/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Dr. Rigolli is a Cardiologist, Physician-Scientist (MD, DPhil), Senior Director and Senior Clinical Trial Physician in Global Drug Development. Her expertise includes CV Imaging, Cardiomyopathies, Heart Failure and Valvular Heart Disease. She currently works at Bristol Myers Squibb.
Dr Rigolli trained in Cardiovascular Medicine and Imaging at the University of Oxford, UK and at the University of Verona, Italy. Her doctoral studies were awarded a DPhil (PhD) from the University of Oxford before moving to the US to work on hypertrophic, rare cardiomyopathies at the University of California, San Diego. Her academic research examined the role of imaging in assessing clinical outcomes and treatment targets in heart failure, aortic stenosis and cardiomyopathies.
Dr. Rigolli is currently developing drugs in cardiomyopathies (HCM) and Heart Failure (HF). She is passionate about clinical trials, publishes in high-impact journals, and has won multiple young investigator awards.
Right ventricular dysfunction is associated with late mortality in severe aortic stenosis: results from a multi-centre outcome study in patients undergoing aortic valve replacement
Event: ESC Congress 2019
Topic: Epidemiology, Prognosis, Outcome
Session: Imaging parameters in valvular heart disease
